The complex web of prescription drug pricing is facing a significant push for simplification as those funding the benefits demand more clarity. A growing number of employers are signaling a preference for rebate-free PBM models, seeking to strip away the opaque financial arrangements that have long defined the relationship between drug manufacturers and pharmacy benefit managers.
For years, the mechanism of “rebates”—payments made by drug manufacturers to PBMs to ensure their medications are placed on a preferred list—has been a point of contention in healthcare policy. While these rebates were originally intended to lower costs, critics argue they have created a system where higher list prices are incentivized because they allow for larger rebates, often leaving the actual patient and the employer paying more at the point of sale.
As an internal medicine physician and health journalist, I have seen how these systemic inefficiencies trickle down to the clinic level, where patients are often surprised by the cost of a life-saving medication despite having comprehensive insurance. The shift toward a transparent, rebate-free approach represents a potential pivot toward a more sustainable and patient-centric model of care.
Survey Results: A Mandate for Transparency
New research highlights a stark desire among employers to move away from traditional pharmacy benefit structures. According to a survey conducted by the communications and reputation management firm Penta Group for Evernorth Health Services, more than 90% of employers agreed that a rebate-free model would improve transparency into prescription drug prices (Penta Group/Evernorth Survey).
The data suggests that the current system is not only expensive but fundamentally confusing for those managing corporate health plans. The survey found that 91% of employers believe an approach that removes rebates is easier to understand (Penta Group/Evernorth Survey). This lack of clarity often makes it difficult for companies to predict their annual healthcare spend or understand why certain medications are prioritized over others.
Beyond the balance sheet, there is a strong human element to this preference. Approximately 90% of those surveyed reported that a rebate-free model would improve drug affordability and increase overall employee satisfaction (Penta Group/Evernorth Survey). When rebates are eliminated and savings are passed directly to the patient, the “sticker shock” at the pharmacy counter is reduced, leading to better medication adherence and improved health outcomes.
Understanding the PBM Influence on Drug Costs
To understand why rebate-free models are gaining traction, We see necessary to define the role of the Pharmacy Benefit Manager (PBM). PBMs act as intermediaries in the drug supply chain, managing prescription drug benefits for payers. Their primary responsibilities include negotiating rebates from manufacturers, creating medication formularies—the lists of drugs covered by a plan—and contracting with pharmacies.
The traditional PBM model relies heavily on these negotiated rebates. However, this creates a potential conflict of interest. Because PBMs may earn a portion of the rebates they negotiate, there is a systemic incentive to favor more expensive drugs that offer higher rebates over lower-cost alternatives that offer none. This dynamic is a primary driver of the “opaque business practices” that have drawn the ire of regulators.
In a rebate-free model, the incentive structure is inverted. Instead of chasing the largest rebate, the focus shifts toward the lowest net cost of the drug. This transparency allows employers to see the actual price of the medication and ensures that savings are not trapped in the middle of the supply chain but are instead used to lower the cost for the end user.
The Regulatory Landscape and Future Outlook
The push from employers coincides with an era of unprecedented scrutiny from lawmakers and federal regulators. PBMs have faced increasing pressure to disclose their pricing structures and rebate agreements. The argument from critics is simple: the current lack of transparency is driving up medication costs for everyone, from the federal government to the individual patient.
This movement toward transparency is part of a broader effort to reform the pharmaceutical supply chain. By removing the “middleman” incentive of the rebate, the industry could move toward a “pass-through” model, where the PBM is paid a flat administrative fee rather than profiting from the spread between the drug’s list price and its net cost.
For employers, this shift is not just about cost-cutting; it is about fiduciary responsibility and employee wellness. When drug prices are predictable and transparent, employers can design more effective benefits packages that prioritize the most clinically effective medications regardless of their rebate potential.
Key Takeaways: The Shift to Rebate-Free PBMs
- Employer Demand: Over 90% of employers surveyed believe rebate-free models increase price transparency.
- Simplicity: 91% of employers find the removal of rebates makes pharmacy benefits easier to understand.
- Patient Impact: 90% of employers believe this shift would improve drug affordability and employee satisfaction.
- The Core Issue: Traditional PBM models may incentivize higher-priced drugs due to the lure of larger manufacturer rebates.
- The Goal: Transitioning to a system where savings are passed directly to patients and payers rather than retained by intermediaries.
The next major checkpoint for this issue will be the continued legislative and regulatory reviews of PBM practices currently underway in various government bodies. These actions are expected to determine whether the industry will move toward a standardized transparency mandate or if the shift to rebate-free models will remain a voluntary choice for employers and their PBM partners.
Do you think a rebate-free model would lower your prescription costs? Share your thoughts in the comments below or share this article with your HR representative to start the conversation.